Drugs / Spikogen
Spikogen
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06355232 | May 2024 → Dec 2025 overdue | COVID-19, influenza | Vaxine Pty Ltd | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05542862 | Sep 2022 → Dec 2023 | COVID-19 | Vaxine Pty Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05279456 | Aug 2022 → Dec 2023 | COVID-19 | Vaxine Pty Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05148871 Comparator | Mar 2022 → Feb 2023 overdue | COVID-19 | Vaxine Pty Ltd | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-07-16 | Vaxine Pty Ltd | Results Promising clinical trial of Vaxine’s Covid-19 vaccine technology. vaxine.net ↗
CinnaGen Co. announced that the results of preliminary analysis of data from the ongoing Phase 2 human clinical trial of SpikoGen vaccine based on Vaxine’s COVID-19 vaccine technology were positive. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-07-16 | Vaxine Pty Ltd | Promising clinical trial of Vaxine’s Covid-19 vaccine technology. vaxine.net ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spikogen | “SpikoGen® vaccine was licensed for use in the Middle East as a primary vaccine course in adults in October 2021.” NCT06355232 ↗4“Spikogen® vaccine, also known as Covax-19™ in Australia, is an adjuvanted recombinant protein Covid-19 vaccine” NCT05279456 ↗ “Spikogen® vaccine is an Advax-CpG55.2 adjuvanted recombinant protein vaccine” NCT06355232 ↗ |
| Known as | Covax-19 | “Spikogen, also known under the Covax-19 tradename in Australia, is based on recombinant SARS-COV-2 spike protein” NCT05148871 ↗1“Spikogen® vaccine, also known as Covax-19™ in Australia, is an adjuvanted recombinant protein Covid-19 vaccine” NCT05279456 ↗ |
| Known as | Spikogen vaccine | “Spikogen vaccine” NCT05279456 ↗ |
| Modality | Vaccine | “Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant” NCT05148871 ↗ |
| Route | Intramuscular | “two intramuscular doses administered 3 weeks apart” NCT05148871 ↗ |